by Raynovich Rod | Feb 7, 2021 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-1 FEB 11, Momentum easing with some good stocks moves, XBI off 1.3% to $165.83. Coronavirus focus stocks are mixed with our holdings doing well. ABT up 1.24%, HOLX up 0.53% and Genmark Diagnostics (GNMK) up 33% to $22.46 on rumors of being acquired, but...
by Raynovich Rod | Jan 14, 2015 | Biopharmaceuticals
Next Generation Clinical Diagnostic Systems We sat in on presentations for two innovative clinical diagnostic companies that have platform products serving big potential markets. Although it may be early to buy these stocks now they should be on your watch list for...
by Raynovich Rod | Jan 25, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
1/28/21 Update-2 VIR Hits $140 yesterday then rolls over to $58+ today! JPMorgan downgraded VIR letting some of the air out of the ballon. The recent speculation may have been about a VIR antibody mirroring the therapeutic potential of the Lilly (LLY) developments....
by Raynovich Rod | Jan 13, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
JPMorgan Healthcare Conference Notes #1: Current Portfolio Positions Focus is Coronavirus diagnostics and vaccines. Gene therapy is poised for next wave: The Conference boosted many stocks as you might expect in a bull market for biotech. We reviewed rather quickly...
by Raynovich Rod | Oct 25, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Macro
Update-3 10/29. 1p EDT…Earnings reports stabilize biopharma stocks. Vaccine stocks strong. Gilead Sciences (GILD) beats but lowers guidance.Needs clinical news on deals. Stock lower. Amgen (AMGN) holds $216 after beat, osteoporosis drug opportunity. Early...
by Raynovich Rod | Sep 28, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 10/6…Apparently a Momentum Market needs constant feeding. Politics are in the forefront. And the COIVID pandemic lingers. Small caps did better IWM down only 0.25%, IJR flat. Large cap biotech was not a place to hide either. Coronavirus winners today...
by Raynovich Rod | Aug 30, 2020 | Biopharmaceuticals, coronavirus vaccine, vaccines
Update-2 Downdraft surprises investors-momentum shift ! We have been talking about this for weeks, How much higher can the FAANG names go? The momentum is unprecedented. Bifurcated market. Well today the sell-off was in full swing with broad damage across the...
by Raynovich Rod | Aug 18, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
We took profits on many longs and shorts in the coronavirus sector so I will need to look at new trades for Q4. Our small longs for now are ABT, AZT, GNMK, GILD, MRNA, MRK, OSUR and TDOC. However We are also long many large caps in addition to above: ABBV, BMY, JNJ,...
by Raynovich Rod | Jul 9, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro, Vaccines
Update-4 7/15 1:30P…Volatlity hits COVID vaccine players; BNTX, INO, NVAX down, MRNA up. Comment from CNBC contributor: “maybe vaccine news is priced in”, shows how hard it is to play daily news flow on coronavirus vaccine stocks. Strong Coronavirus...
by Raynovich Rod | Jun 28, 2020 | Biopharmaceuticals, Clinical Diagnostics and Tools, coronavirus vaccine, vaccines
Update-5 JY 7 After close with NASDAQ down 0.86%, but biotechs hold. Genmark (GNMK) up 10.33% AH to $17.22 on Preliminary q2 Results. Revs of $40.1M, a 118% increase over Q2 2019, Placed 71 new ePlex analyzers for a total installed base of 650. Added to VIR Bio (VIR)...
